CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Drug Reimbursement Recommendation - cyclosporine (Verkazia)

Published on: November 20, 2019
Result type: News

Today, CADTH has issued recommendations for:

cyclosporine (Verkazia)

Indications : Severe vernal keratoconjunctivitis, pediatric (≥4 years)
Recommendation : Reimburse with clinical criteria and/or conditions

For more information